Orfalea price cut signals soft Ventura County office market
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Patent ruling in favor of Amgen has shares skyrocketing
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Thousand Oaks makes interim city manager permanent
After serving as interim city manager for Thousand Oaks since July 5, 2016, Andrew Powers was brought on permanently Jan. 10 in a special meeting of the Thousand Oaks City Council. Powers had previously served as assistant city manager and in community and media relations roles for Ventura and Raleigh, N.C. He received his bachelor’s Read More →
Amgen updates agreement with DaVita for dialysis treatment
Thousand Oaks biotech company Amgen entered into a six-year supply agreement with DaVita for dialysis treatments, the company announced on Jan. 9. Under the terms of the new agreement, Amgen will supply DaVita with Epogen and Aranesp for agents to stimulate red blood cells in dialysis treatment in the United States and Puerto Rico. The Read More →
Amgen partners with Immatics Biotechnologies to develop cancer drugs
Thousand Oaks biotech company Amgen formed a potential $500 million partnership with Immatics Biotechnologies GmbH to research and develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancers, the company announced on Jan. 9. Under the terms of the agreement, Immatics will receive $30 million upfront and can receive more than $500 million in development, regulatory Read More →
Amgen shares climb after judge upholds Repatha patents
A ruling in a patent law case regarding a new anti-cholesterol drug involving Thousand Oaks biotech giant Amgen has skyrocketed Amgen shares. Amgen filed a patent infringement lawsuit against Sanofi and Regeneron in the U.S. District Court of Delaware in October 2014 to block the development and sale of the drug Praluent, which was developed Read More →
Corporate tax cut could fuel biotech mergers, acquisitions
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
